Afirma genomic sequencing classifier laboratory testing
Ended Awarded Last action
- Contract number
- W81K0023F0175
- Awardee
-
Veracyte, Inc. UEI JS7GBP6LCMN6
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $150,400
Award facts
- Opportunity
-
- W81K0023Q0149 Solicitation number
- Contract value 66% obligated
-
- $150,400.00 Current, with exercised options
- $227,200.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- South San Francisco, CA 94080, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $76,800 | |
| Exercise an Option | $0 | |
| Funding Only Action | $73,600 | |
| Original award | $0 |
About this award
The Defense Health Agency awarded a $227.2K delivery order to Veracyte, Inc. for Afirma Genomic Sequencing Classifier laboratory testing with a completion date of September 30, 2026. This firm fixed-price delivery order, awarded October 1, 2023, with no small business set-aside, will be performed in South San Francisco, California. The award falls under Veracyte's existing indefinite delivery vehicle on the GSA Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II), which streamlines the federal procurement process for specialized genomic testing services across the Department of Defense's healthcare system.
Veracyte, Inc., a medical diagnostic company headquartered in South San Francisco, specializes in advanced genomic testing for precision medicine applications. The Afirma Genomic Sequencing Classifier is a proprietary molecular diagnostic test that assesses thyroid nodule malignancy risk through gene expression pattern analysis. Veracyte maintains an established federal contractor relationship with the Defense Health Agency and other federal healthcare entities, delivering genomic testing services to support personalized cancer care initiatives across military healthcare beneficiaries and service members. This delivery order represents the company's ongoing role in providing specialized diagnostic capabilities to enhance clinical decision-making within the federal healthcare system.
Quick answers
Who was awarded contract W81K0023F0175?
W81K0023F0175 was awarded to Veracyte, Inc. by Medical Command (Department of the Army) on October 1, 2023.
How much is contract W81K0023F0175 worth?
The government has obligated $150,400 on W81K0023F0175. Its potential value, with all options, is $227,200.
Which agency awarded contract W81K0023F0175?
Medical Command (Department of the Army) awarded W81K0023F0175, with funding from Defense Health Agency (Department of Defense).
Is contract W81K0023F0175 an order under another contract?
Yes. W81K0023F0175 is a delivery order under 36F79718D0524, a federal supply schedule, on Medical Laboratory Testing and Analysis Services (FSS-621-II).
Was contract W81K0023F0175 competed?
The extent of competition for W81K0023F0175 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award